These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8202533)

  • 1. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.
    Kaplan AH; Michael SF; Wehbie RS; Knigge MF; Paul DA; Everitt L; Kempf DJ; Norbeck DW; Erickson JW; Swanstrom R
    Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5597-601. PubMed ID: 8202533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.
    Ho DD; Toyoshima T; Mo H; Kempf DJ; Norbeck D; Chen CM; Wideburg NE; Burt SK; Erickson JW; Singh MK
    J Virol; 1994 Mar; 68(3):2016-20. PubMed ID: 8107264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.
    Borman AM; Paulous S; Clavel F
    J Gen Virol; 1996 Mar; 77 ( Pt 3)():419-26. PubMed ID: 8601776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
    Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease.
    Mo H; Markowitz M; Majer P; Burt SK; Gulnik SV; Suvorov LI; Erickson JW; Ho DD
    AIDS Res Hum Retroviruses; 1996 Jan; 12(1):55-61. PubMed ID: 8825619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.
    Gong YF; Robinson BS; Rose RE; Deminie C; Spicer TP; Stock D; Colonno RJ; Lin PF
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2319-26. PubMed ID: 10952574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.
    Partaledis JA; Yamaguchi K; Tisdale M; Blair EE; Falcione C; Maschera B; Myers RE; Pazhanisamy S; Futer O; Cullinan AB
    J Virol; 1995 Sep; 69(9):5228-35. PubMed ID: 7636964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects.
    Lech WJ; Wang G; Yang YL; Chee Y; Dorman K; McCrae D; Lazzeroni LC; Erickson JW; Sinsheimer JS; Kaplan AH
    J Virol; 1996 Mar; 70(3):2038-43. PubMed ID: 8627733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants.
    Pazhanisamy S; Stuver CM; Cullinan AB; Margolin N; Rao BG; Livingston DJ
    J Biol Chem; 1996 Jul; 271(30):17979-85. PubMed ID: 8663409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of the human immunodeficiency virus type 1 protease: effects on viral replication capacity and protease robustness.
    Capel E; Martrus G; Parera M; Clotet B; Martínez MA
    J Gen Virol; 2012 Dec; 93(Pt 12):2625-2634. PubMed ID: 22933665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.
    Patick AK; Rose R; Greytok J; Bechtold CM; Hermsmeier MA; Chen PT; Barrish JC; Zahler R; Colonno RJ; Lin PF
    J Virol; 1995 Apr; 69(4):2148-52. PubMed ID: 7884862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure.
    Suñé C; Brennan L; Stover DR; Klimkait T
    Clin Microbiol Infect; 2004 Feb; 10(2):119-26. PubMed ID: 14759236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.
    Yates PJ; Hazen R; St Clair M; Boone L; Tisdale M; Elston RC
    Antimicrob Agents Chemother; 2006 Mar; 50(3):1092-5. PubMed ID: 16495277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.
    Yoshimura K; Kato R; Kavlick MF; Nguyen A; Maroun V; Maeda K; Hussain KA; Ghosh AK; Gulnik SV; Erickson JW; Mitsuya H
    J Virol; 2002 Feb; 76(3):1349-58. PubMed ID: 11773409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase.
    Baldwin ET; Bhat TN; Liu B; Pattabiraman N; Erickson JW
    Nat Struct Biol; 1995 Mar; 2(3):244-9. PubMed ID: 7773792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.
    Baxter JD; Schapiro JM; Boucher CA; Kohlbrenner VM; Hall DB; Scherer JR; Mayers DL
    J Virol; 2006 Nov; 80(21):10794-801. PubMed ID: 16928764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.
    Condra JH; Schleif WA; Blahy OM; Gabryelski LJ; Graham DJ; Quintero JC; Rhodes A; Robbins HL; Roth E; Shivaprakash M
    Nature; 1995 Apr; 374(6522):569-71. PubMed ID: 7700387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.
    Otto MJ; Garber S; Winslow DL; Reid CD; Aldrich P; Jadhav PK; Patterson CE; Hodge CN; Cheng YS
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7543-7. PubMed ID: 8356053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
    Ntemgwa M; Brenner BG; Oliveira M; Moisi D; Wainberg MA
    Antimicrob Agents Chemother; 2007 Feb; 51(2):604-10. PubMed ID: 17116674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.